Overview
Corporate Profile
At Gamida Cell, we are cell therapy pioneers working to turn cells into powerful therapeutics. Our proprietary technology leverages nicotinamide (NAM), which plays a key role in the metabolic reprogramming of cells, to expand the number of cells and enhance cellular functionality and phenotype. Our therapeutic product and candidates aim to offer potentially curative treatment options for patients living with blood cancers.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Latest News
View All
Mar 27, 2024
Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update
Read More
Mar 27, 2024
Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management
Read More
Nov 20, 2023
Gamida Cell to Present Corporate Highlights at the Piper Sandler 35th Annual Healthcare Conference
Read More
Nov 14, 2023
Gamida Cell Reports Third Quarter 2023 Financial Results and Provides Company Update
Read More
Nov 04, 2023
Gamida Cell Presents New Data on Allogeneic Stem Cell Therapy Omidubicel and Natural Killer (NK) Cell Therapy Candidate GDA-201 at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Read More
Oct 16, 2023
Gamida Cell Reports Preliminary Data from Phase 1 Study of Natural Killer (NK) Cell Therapy Candidate GDA-201
Read More
Oct 02, 2023
Gamida Cell to Present Corporate Highlights at 2023 Cell & Gene Meeting on the Mesa
Read More
Sep 28, 2023
Gamida Cell to Present at Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting
Read More
Aug 31, 2023
Gamida Cell to Present Corporate Highlights at the H.C. Wainwright 25th Annual Global Investment Conference
Read More
Aug 14, 2023
Gamida Cell Reports Second Quarter and First Half 2023 Financial Results and Provides Company Update
Read More
Upcoming Events
More events are coming soon.
Recent Events
Corporate Fact Sheet
Corporate Presentation
More information is coming soon.
In the News
March 10, 2023
Source
Insightscare Magazine
February 7, 2023
Source
BioSpectrum
February 6, 2023
Source
Nasdaq
January 25, 2023
Source
Rare Disease Advisor
January 19, 2023
Source
Pharmaceutical Technology
December 29, 2022
Source
Globes
September 23, 2022
Source
BioSpace
September 5, 2022
Source
The Wall Street Transcript
August 16, 2022
Source
Cell & Gene Therapy Insights
December 1, 2021
Source
Life Science Leader
Investor & Media Contact
Ryan Pugliares
Gamida Cell Ltd.
IRPR@gamida-cell.com